All In Biotech

Drug Trial Radar · NCT05081245

ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)

A Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD).

Last checked: Nov 19, 2026Latest source record: May 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 168 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

168

Actual

Start

Sep 13, 2022

Primary completion

Mar 10, 2026

Study completion Apr 17, 2026

Sponsor

Lead sponsor
MapLight TherapeuticsIndustry
Sponsor type
Industry
First posted
Oct 18, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ML-004-002 is a multi-center, randomized, double-blind, parallel-group, placebo-controlled study that will enroll approximately 150 adolescent and adult subjects with ASD. The primary objective is to evaluate the efficacy of ML-004 compared with placebo in the improvement of social communication deficits in subjects with ASD.

Conditions

  • Autism Spectrum Disorder

Interventions

  • ML-004 (IR)/(ER) tabletDrug

    Participants will receive ML-004 once daily.

  • ML-004 PlaceboDrug

    Participants will receive matching placebo once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in Autism Behavior Inventory (ABI)-Social Communication Domain ScoreTime frame: Baseline up to Day 110

Locations

29 sites in 3 countries. Site status is shown where the registry gives one.

  • Harmonex Neuroscience Research

    Dothan, Alabama

  • Southwest Autism Research & Resource Center, Clinical Research

    Phoenix, Arizona

  • Cortica Healthcare

    Glendale, California

  • NRC Research Institute

    Orange, California

  • Cortica

    San Rafael, California

  • Yale Child Study Center

    New Haven, Connecticut

  • Children's National Health System - The Children's Research Institute (CRI)

    Washington D.C., District of Columbia

  • Abba Medical Group

    Miami, Florida

  • APG Research, LLC

    Orlando, Florida

  • University of South Florida Psychiatry and Behavioral Neurosciences

    Tampa, Florida

  • Neurobehavioral Medicine Group

    Bloomfield Hills, Michigan

  • University of Missouri, Thompson Center for Autism & Neurodevelopmental Disorders

    Columbia, Missouri

  • Jersey Shore University Medical Center

    Neptune City, New Jersey

  • Nathan Kline Institute for Psychiatric Research

    Orangeburg, New York

  • Richmond Behavioral Associates

    Staten Island, New York

  • Center for Autism and the Developing Brain, New York State Psychiatric Institute

    White Plains, New York

  • Ohio State University Nisonger Center

    Columbus, Ohio

  • Suburban Research Associates

    Media, Pennsylvania

  • BioBehavioral Research of Austin

    Austin, Texas

  • Red Oak Psychiatry Associates, PA

    Houston, Texas

  • Road Runner Research, Ltd.

    San Antonio, Texas

  • Family Psychiatry of The Woodlands

    The Woodlands, Texas

  • Cedar Clinical Research

    Draper, Utah

  • Virginia Commonwealth University

    Richmond, Virginia

  • Brain and Mind Centre

    Camperdown, New South Wales, Australia

  • The Royal Children's Hospital, Murdoch Children's Research Institute

    Parkville, Victoria, Australia

  • OCT Research ULC (dba Okanagan Clinical Trials)

    Kelowna, British Columbia, Canada

  • Lawson Health Research Institute/ London Health Sciences Centre

    London, Ontario, Canada

  • Holland Bloorview Kids Rehabilitation Hospital

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.